Is Mankind Pharma overvalued or undervalued?

As of 26 September 2025, Mankind Pharma's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. The company is currently considered overvalued. Key ratios include a PE Ratio of 54.02, an EV to EBITDA of 31.27, and a Price to Book Value of 7.15, all of which are significantly higher than industry norms.
In comparison to its peers, Mankind Pharma's PE Ratio is notably higher than Sun Pharma's 33.18 and Cipla's 22.45, which suggests that Mankind is trading at a premium relative to these companies. Additionally, the company has underperformed against the Sensex, with a year-to-date return of -13.96% compared to the Sensex's 2.93%, further reinforcing the notion that Mankind Pharma is overvalued in the current market environment.